Curriculum vitae

1999 – 2002: Medizinstudium an der Ruhr-Universität Bochum

2002 – 2005: Medizinstudium an der Universität Duisburg-Essen

2005 – 2006: Medizinstudium an der Ruhr-Universität Bochum

2006 – 2015: Wissenschaflicher Mitarbeiter und Assistenzarzt in den Kliniken für Angiologie, Endokrinologie, Gastroenterologie und Hepatologie, Kardiologie und Nephrologie innerhalb des Zentrums für Innere Medizin sowie Innere Klinik (Tumorforschung) und Kliniken für Hämatologie und Knochenmarktransplantation innerhalb des Zentrums für konservative Onkologie

2016 – 2017: Wissenschaftlicher Mitarbeiter (Oberarzt) und Leiter einer Arbeitsgruppe (Labor für thoraxonkologische Forschung) der Inneren Klinik (Tumorforschung), Universitätsklinkum Essen

2017 – 2021: Oberarzt der Klinik für Internistische Onkologie und onkologische Palliativmedizin, Evangelische Huyssensstiftung, Evangelische Kliniken Essen-Mitte

2021 – 2024: Leitender Oberarzt der Klinik für Internistische Onkologie und onkologische Palliativmedizin, Evangelische Huyssensstiftung, Evangelische Kliniken Essen-Mitte

2018 – 2022: Angestellter Facharzt im Medizinischen Versorgungszentrum Hämatologie und Onkologie Essen gGmbH   

2024 – heute: Leiter der Sektion Thoraxonkologie, Klinik für Pneumologie und Infektiologie, Evang. Krankenhaus Herne-Eickel

Anerkennung, Stipendien und Auszeichnungen

2010 – 2012: “International Association for the Study of Lung Cancer (IASLC) Fellowship Award”

2011: “American Society of Clinical Oncology (ASCO) Foundation Merit Award”

2015: Anerkennung als Facharzt für Innere Medizin mit der Schwerpunktbezeichnung Hämatologie / Onkologie

Mitglied in wissenschaftlichen Fachgesellschaften

ASCO (American Society of Clinical Oncology)

DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie)

ESMO (European Society of Medical Oncology)

IASLC (International Association for the Study of Lung Cancer)

Prüfarzttätigkeiten bei klinischen Studien (Hauptverantwortlicher Prüfarzt)

BI1199.93: „Double blind, randomized, multicenter, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combnation with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma”

MORAb-009-201: „A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma”

BAY 94-9343 / 15743: „A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy”

CheckMate743: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Roche Immotion WO29637: „A phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma“

CheckMate 592: “An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)”

AIO-YMO/TRK-0416: “Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC”

KEYLYNK-006: „A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer”

KEYLYNK-008: „A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)”

NICITA: “Nivolumab with chemotherapy in pleural mesothelioma after surgery”

CONTACT-01 (GO41892): A Phase III, multicenter, randomized, open-label, controlled Study to evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab given in Combination with Cabozantinib versus Docetaxel Monotherapy in Patients with Metastatic Non-Small Cell Lung Cancer previously treated with an Anti-PD-L1/PD-1 Antibody and Platinum containing Chemotherapy.

MK3475-789: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants.

CheckMate 73L (CA209-73L): A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

DOLPHIN: A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer.

SAPPHIRE/MIRATI 516-005: “A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy”

MIRATI 849-012: “A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation”

MyRisk/IBA1160: “Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study”

CA224104/RELATIVITY-104: “A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)”

IMforte/GO43104: “A Phase III, randomized, open-label, Multicenter Study of Lurbinectidin in Combination with Atezolizumab compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Ffollowing First-Line

Induction Therapy With Carboplatin, Etoposide and Atezolizumab”

ANTELOPE: “Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma